After last year's ImmunoGen pact, Vertex finds another conditioning agent...
Vertex is partnering with a US and South Korean biotech to see if it can offer patients a better conditioning agent to make way for an infusion of Casgevy, the biotech’s recently approved sickle cell...
View ArticleBain-backed Cardurion raises $260M to fund ex-Imara drug, buy more cardio assets
Cardurion Pharmaceuticals is going shopping for more cardio drug candidates. The Burlington, MA-based biotech, which launched in 2017 with a Takeda partnership, has raised a $260 million Series B round...
View ArticleClik here to view.
Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly...
Sionna Therapeutics snagged the exclusive worldwide license to three of AbbVie’s cystic fibrosis drug candidates as the biotech aims to beef up its work in the genetic condition and fill gaps not...
View ArticleScorpion raises $150M for next wave of targeted cancer therapies
Scorpion Therapeutics has a fresh $150 million to work with as it moves an experimental breast cancer drug through clinical trials in an effort to best Novartis’ targeted therapy Piqray. This latest...
View ArticleClik here to view.
A teenager faced constant seizures. Could a drug developed just for him stop...
SAN DIEGO — Connor Dalby’s shrieks filled his playroom, and the rest of the house. The teenager hushed when his mom, Kelley, asked a long-coming question: “Are you ready for the big day tomorrow?” He...
View ArticleClik here to view.
Q&A: Jefferies analyst Brian Tanquilut talks Walgreens’ retreat from primary...
Retailers have struggled immensely to gain a firm foothold in healthcare delivery. Last month, Walgreens said it’ll cut its stake in primary care chain VillageMD after closing more than 100 clinic...
View ArticleSOTIO, Biocytogen to jointly develop antibodies; Pliant's mid-stage liver...
Plus, news about Vertex, Genomics and Lantheus: SOTIO, Biocytogen team up on antibodies: SOTIO will get the option to license bispecific antibodies designed using Biocytogen’s RenLite platform. These...
View ArticleFDA warns Chinese drugmaker for serious GMP record violations
The FDA on Tuesday released a warning letter sent to China-based drugmaker Jiangsu Hengrui Pharmaceuticals, finding the company failed at multiple levels to ensure its Good Manufacturing Practice (GMP)...
View ArticleAstraZeneca criticizes CMS guidance in appeal over price negotiations
More than four months after losing a legal attempt to overturn parts of the Inflation Reduction Act’s drug price negotiations, AstraZeneca is firing back in a court appeal, arguing that CMS’ latest...
View ArticleFederal judge dismisses Hawaii’s lawsuit against top three PBMs
A federal judge has tossed a lawsuit against the three largest pharmacy benefit managers, pouring cold water on the state of Hawaii’s claim that the companies unlawfully inflate drug prices. Friday’s...
View ArticleLarge group of state attorneys general backs Oregon drug price transparency law
In the latest chapter of years of legal back-and-forth, attorneys general from 20 states and the District of Columbia have asked a federal appeals court to reverse a decision that an Oregon drug price...
View ArticleClik here to view.
Biotech industry flirts with XBI milestone as it surpasses $100
As bankers and investors were getting their Monday afternoon pick-me-up coffee, they might have noticed a slight upswing in the biotech industry’s main stock index. For an approximately 70-minute...
View ArticleFDA again rejects Orexo's nasal spray for opioid overdose rescue
For a second time, the FDA has turned away Orexo’s nasal spray treatment for opioid overdoses. The company will need to complete another “human factor” study before resubmitting its application, Orexo...
View ArticleAfter a handful of stumbles, argenx doubles down on pipeline-in-a-product...
Five years ago, the Dutch biotech argenx outlined plans to test its drug Vyvgart in more than a dozen autoimmune conditions. By removing the self-sabotaging antibodies believed to be responsible for...
View ArticleRenalys raises $37.8M to take Travere's kidney disease drug into Phase 3...
Japanese biotech Renalys Pharma has raised $37.8 million (¥6 billion) in a Series A round to work on an approval in Japan for the drug Filspari in a rare kidney disease. Renalys took over the rights to...
View ArticleCaribou to slash preclinical allogeneic CAR-NK work, lay off 12% of staff
Caribou Biosciences is cutting its CAR-NK research and laying off 21 employees, or 12% of its staff, the company announced Tuesday. “We are undertaking this reduction to extend our cash runway by...
View Article#ASRS24: Adverum prepares pivotal study for wet AMD gene therapy, touts Phase...
Adverum Biotechnologies’ eye disease gene therapy has traversed a rocky road of safety troubles, but the company — presenting new Phase 2 data in wet AMD — now believes it has a clear shot to a pivotal...
View ArticleGenentech ends SHP2 deal with Relay Therapeutics after other pharma exits
Roche’s Genentech is scrapping a collaboration and license agreement with Relay Therapeutics surrounding the biotech’s clinical-stage oral SHP2 inhibitor. It’s the latest pharmaceutical company to...
View ArticleManufacturing investment firm BioProcess360 launches with $100M for...
With its first round of $100 million in hand, a new investment firm has emerged to help fund and mentor up-and-coming businesses that are developing tools and tech that can help reduce manufacturing...
View Article#ASRS24: 4DMT builds out case for wet AMD gene therapy with new Phase 2 data
4D Molecular Therapeutics presented new Phase 2 data for its wet AMD gene therapy, showing a durable response in a broad patient population, as it prepares to enter Phase 3 testing early next year. The...
View Article